Sign in
Taking people in PolandPhase 1

Tests anti-CD19 CAR-T cells for safety in adults with B-cell non-Hodgkin lymphoma

Tests anti-CD19 CAR-T cells in adults with B-cell non-Hodgkin lymphoma.

Key facts

Who runs it
Wroclaw Medical University
Where
Wroclaw, PolandSee the site
Registry title
Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).
Status
Recruiting
Phase
Phase 1
People taking part
18 people, planned
Started
25 Jun 2025
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
13 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with B-cell non-Hodgkin lymphoma, such as DLBCL or high grade B-cell lymphoma, to test the safety of anti-CD19 CAR-T cells.

Age
18 years or older
Sex
Women and men can join.
Disease stage
B-cell non-Hodgkin lymphoma, including DLBCL, aggressive B-cell lymphoma and high grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement. The record gives no further stage details.

Where in Poland

  • Wroclaw Medical UniversityWroclaw, PolandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests anti-CD19 CAR-T cells for safety in adults with B-cell non-Hodgkin lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 March 2026